Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 13/20 | 0.66 |
| ▸ | CNR1 | P21554 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GRN | P28799 | 1/20 | 0.46 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.45 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL351695 | 0.89 | CNR2 (0.52) | CNR2CNR1KDM4EGRNSORT1 | |
| SCHEMBL353275 | 0.81 | CNR2 (0.57) | CNR2CNR1KDM4EGRNSORT1 | |
| SCHEMBL469410 | 0.80 | CNR2 (1.00) | CNR2CNR1MAPK13MAPTMAPK12 | |
| SCHEMBL352506 | 0.76 | KDM4E (0.42) | CNR2CNR1KDM4EGRNSORT1 | |
| SCHEMBL353098 | 0.73 | CNR2 (0.49) | CNR2CNR1KDM4EGRNSORT1 | |
| SCHEMBL351492 | 0.72 | GRN (0.48) | CNR2KDM4EGRNSORT1MAPT | |
| SCHEMBL1465183 | 0.71 | CNR2 (0.78) | CNR2CNR1MAPK13MAPTMAPK12 | |
| SCHEMBL352111 | 0.70 | PHGDH (0.47) | CNR2CNR1KDM4EGRNSORT1 | |
| SCHEMBL1464857 | 0.70 | CNR2 (0.82) | CNR2CNR1KDM4EGRNSORT1 | |
| SCHEMBL12519203 | 0.70 | CNR2 (0.79) | CNR2CNR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2418207-A1 | Sulfone compounds which modulate the CB2 receptor | Boehringer Ingelheim International GmbH (DE) | 2012-02-15 | — | — | EP | disclosed |
| US-20120015988-A1 | Sulfone Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-19 | — | — | US | disclosed |
| US-20120015988-A1 | Sulfone Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-19 | — | — | US | disclosed |
| US-20120015988-A1 | Sulfone Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-19 | — | — | US | disclosed |
| EP-2283001-A2 | SULFONE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | Boehringer Ingelheim International GmbH (DE) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009140089-A2 | SULFONE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-11-19 | — | — | WO | disclosed |
| WO-2009140089-A2 | SULFONE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015988-A1 | Sulfone Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, TRPV1 | CNR2 1/4885CNR1 2/4885KDM4E 2157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.